Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Non-Current Deffered Revenue: 2012-2021

Historic Non-Current Deffered Revenue for Cytokinetics (CYTK) over the last 8 years, with Dec 2021 value amounting to $87.0 million.

  • Cytokinetics' Non-Current Deffered Revenue changed negligibly% to $87.0 million in Q1 2022 from the same period last year, while for Mar 2022 it was $87.0 million, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $87.0 million for FY2021, which is negligibly% changed negligibly from last year.
  • Per Cytokinetics' latest filing, its Non-Current Deffered Revenue stood at $87.0 million for FY2021, which was down 0.00% from $87.0 million recorded in FY2020.
  • In the past 5 years, Cytokinetics' Non-Current Deffered Revenue ranged from a high of $87.0 million in FY2020 and a low of $15.0 million during FY2017.
  • Its 2-year average for Non-Current Deffered Revenue is $87.0 million, with a median of $87.0 million in 2021.